Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2
Oto Rhino Laryngologica Indonesiana · 2011
DOI: 10.32637/orli.v41i1.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oto Rhino Laryngologica Indonesiana, 2011. Verfasst von Bambang Hariwiyanto und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Nasopharyngeal carcinoma (NPC) is one of the most common among head and neck malignancies, especially in some Asian countries. Epstein-Barr Virus (EBV) is one of the agent causing NPC, expressing many proteins such as Epstein-Barr nucleus antigen (EBNA). Expression of EBNA theoretically influencing therapy KNF outcome.
Purpose
To differentiate therapy result between NPC expressed positive EBNA1 and EBNA2 compared with NPC expressed negative EBNA1 and EBNA2.
Method
Nested case control study toward 28 complete remission NPC patients and 28 partial remission NPC patients post treatment.
Result
There was no significant difference in therapy outcome between NPC with EBNA1 expression =4.90 compared to EBNA1
Zitieren
APA
Hariwiyanto, B., Sastrowiyoto, S., Mubarika, S., & Masesadji, S. (2011). Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2. Oto Rhino Laryngologica Indonesiana. https://doi.org/10.32637/orli.v41i1.52
Vancouver
Hariwiyanto B, Sastrowiyoto S, Mubarika S, Masesadji S. Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2. Oto Rhino Laryngologica Indonesiana. 2011. doi:10.32637/orli.v41i1.52
BibTeX
@article{Hariwiyanto2011,
author = {Hariwiyanto, Bambang and Sastrowiyoto, Soenarto and Mubarika, Sofia and Masesadji, Salugu},
title = {Kajian terhadap hasil terapi karsinoma nasofaring berdasarkan EBNA1 dan EBNA2},
journal = {Oto Rhino Laryngologica Indonesiana},
year = {2011},
doi = {10.32637/orli.v41i1.52}
}
EUVIMED